May 10, 2023

Clinical Trial Application for 7MW3711 - an Innovative Drug Developed by Mabwell's ADC Platform, Accepted by NMPA

➞

Apr 26, 2023

Mabwell's First Self-commercialized Drug Reached its National Logistics Ceremony

➞

Apr 05, 2023

China’s First Nectin-4 Targeted ADC Drug 9MW2821 Clinical Progress Released

➞

Mar 31, 2023

The World's Second Approved Biosimilars of Denosumab (MAILISHU)

➞

Mar 16, 2023

Mabwell's Clinical Trial Application for 9MW3811 Accepted by NMPA

➞

Mar 13, 2023

Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011

➞

Mar 03, 2023

Mabwell's Clinical Trial Application for 9MW3911 Injection - An Innovative Drug, Accepted by NMPA

➞

Feb 27, 2023

First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND

➞

Feb 05, 2023

Accelerating Development of Mabwell's ADC Plateform: Clinical Trial Application for an Innovative Drug (9MW2921) Accepted by NMPA

➞

Jan 20, 2023

$412.5 Million Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

➞